MilliporeSigma
  • Home
  • Search Results
  • The osteoblastogenesis potential of adipose mesenchymal stem cells in myeloma patients who had received intensive therapy.

The osteoblastogenesis potential of adipose mesenchymal stem cells in myeloma patients who had received intensive therapy.

PloS one (2014-04-12)
Hsiu-Hsia Lin, Shiaw-Min Hwang, Shang-Ju Wu, Lee-Feng Hsu, Yi-Hua Liao, Yi-Shuan Sheen, Wen-Hui Chuang, Shang-Yi Huang
ABSTRACT

Multiple myeloma (MM) is characterized by advanced osteolytic lesions resulting from the activation of osteoclasts (OCs) and inhibition of osteoblasts (OBs). OBs are derived from mesenchymal stem cells (MSCs) from the bone marrow (BM), however the pool and function of BMMSCs in MM patients (MM-BMMSCs) are reduced by myeloma cells (MCs) and cytokines secreted from MCs and related anti-MM treatment. Such reduction in MM-BMMSCs currently cannot be restored by any means. Recently, genetic aberrations of MM-BMMSCs have been noted, which further impaired their differentiation toward OBs. We hypothesize that the MSCs derived from adipose tissue (ADMSCs) can be used as alternative MSC sources to enhance the pool and function of OBs. Therefore, the purpose of this study was to compare the osteogenesis ability of paired ADMSCs and BMMSCs in MM patients who had completed intensive therapy. Fifteen MM patients who had received bortezomib-based induction and autologous transplantation were enrolled. At the third month after the transplant, the paired ADMSCs and BMMSCs were obtained and cultured. Compared with the BMMSCs, the ADMSCs exhibited a significantly higher expansion capacity (100% vs 13%, respectively; P = .001) and shorter doubling time (28 hours vs 115 hours, respectively; P = .019). After inducing osteogenic differentiation, although the ALP activity did not differ between the ADMSCs and BMMSCs (0.78 U/µg vs 0.74±0.14 U/µg, respectively; P = .834), the ADMSCs still exhibited higher calcium mineralization, which was determined using Alizarin red S (1029 nmole vs 341 nmole, respectively; P = .001) and von Kossa staining (2.6 E+05 µm2 vs 5 E+04 µm2, respectively; P = .042), than the BMMSCs did. Our results suggested that ADMSCs are a feasible MSC source for enhancing the pool and function of OBs in MM patients who have received intensive therapy.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Sodium thiosulfate, ReagentPlus®, 99%
Sigma-Aldrich
Sodium thiosulfate, purum p.a., anhydrous, ≥98.0% (RT)
USP
Ascorbic acid, United States Pharmacopeia (USP) Reference Standard
Ascorbic acid, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Sodium thiosulfate, ≥99.99% trace metals basis
Supelco
Ascorbic Acid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-Ascorbic acid, powder, suitable for cell culture, γ-irradiated
Sigma-Aldrich
L-Ascorbic acid, BioXtra, ≥99.0%, crystalline
Sigma-Aldrich
L-Ascorbic acid, meets USP testing specifications
Sigma-Aldrich
L-Ascorbic acid, reagent grade
Sigma-Aldrich
L-Ascorbic acid, suitable for plant cell culture
Sigma-Aldrich
L-Ascorbic acid, reagent grade, crystalline
Sigma-Aldrich
Sodium thiosulfate solution, 2 g/dL in deionized water
Sigma-Aldrich
Cetylpyridinium chloride, meets USP testing specifications
Sigma-Aldrich
L-Ascorbic acid, suitable for cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
L-Ascorbic acid, FCC, FG
Sigma-Aldrich
L-Ascorbic acid, BioUltra, ≥99.5% (RT)
Sigma-Aldrich
L-Ascorbic acid, 99%
Sigma-Aldrich
L-Ascorbic acid, tested according to Ph. Eur.
Sigma-Aldrich
L-Ascorbic acid, puriss. p.a., ≥99.0% (RT)
Supelco
L-Ascorbic acid, analytical standard
Sigma-Aldrich
L-Ascorbic acid, ACS reagent, ≥99%
Sigma-Aldrich
L-Ascorbic acid, puriss. p.a., ACS reagent, reag. ISO, Ph. Eur., 99.7-100.5% (oxidimetric)
Cetylpyridinium chloride, European Pharmacopoeia (EP) Reference Standard
Supelco
L-Ascorbic acid, certified reference material, TraceCERT®
USP
Cetylpyridinium chloride, United States Pharmacopeia (USP) Reference Standard